Want to join the conversation?
Specialty pharma company $MNK said the US FDA has granted its request for a Fast-Track designation for its Investigational New Drug application for Synacthen Depot for treating Duchenne muscular dystrophy. Synacthen Depot is approved and marketed outside US for some autoimmune and inflammatory conditions but has not been approved in the US.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.